Search

Displaying results 5261 - 5270 of 10000 in total
  1. Drug

    Cucurbita pepo subsp. ovifera whole

    go.drugbank.com/drugs/DB15592
    Approved

    Cucurbita pepo subsp. ovifera whole allergenic extract is used in allergenic testing.

  2. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

  3. Drug

    WL-1002

    go.drugbank.com/drugs/DB05346
    Experimental

    WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.

  4. Drug

    Acetyldigoxin

    go.drugbank.com/drugs/DB13691
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Linopirdine

    go.drugbank.com/drugs/DB13806
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  7. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  8. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental

  9. Drug

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10798
    ApprovedInvestigational

    grown in another culture. … Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  10. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    It was last known to be in phase III clinical trials. … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.